Highlights AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 09:35:13 2024-06-28 EDT			5-day change	1st Jan Change
1,667 ^SEK	+0.51%		+0.42%	+23.31%

06-27	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
06-26	European Equities Close Lower in Wednesday Trading	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	06-27	RE
European Equities Close Lower in Wednesday Trading	06-26	MT
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	06-26	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	06-25	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	06-25	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	06-25
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	06-25	MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	06-25	MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	06-25	MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	06-25	MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	06-25	CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	06-25	RE
AstraZeneca: inconclusive trial for Infinzi in NSCL	06-25	CF
AstraZeneca: inconclusive trial for Infinzei in NSCL	06-25	CF
AstraZeneca details mixed findings from cancer drug trials	06-25	AN
Correction: AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT
AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	06-25	MT
AstraZeneca's Adjuvant Lung Cancer Drug Fails to Improve Disease-free Survival in Late-stage Trial	06-25	MT
AstraZeneca's Imfinzi Gets Positive Results in Bladder Cancer Trial	06-25	DJ
Mixed bag for Astra drug; Landsec ups Bluewater stake	06-25	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm